Clinical outcome after progressing to frontline and second-line anti–PD-1/PD-L1 in advanced urothelial cancer
European Urology Nov 14, 2019
de Liaño Lista AG, et al. - A retrospective analysis of urothelial carcinoma (UC) persons progressing to frontline or later-line anti–PD-1/PD-L1 therapy in ten European institutions was done between March 2013 and September 2017 in order to investigate the outcome of UC people who received subsequent systemic treatment (SST) and no SST following progressing to immune checkpoint inhibitors (ICIs). Two hundred and seventy UC persons with PD to ICIs (69 frontline, 201 later line) were assessed. It was found out that individuals progressing to frontline ICIs were at risk of early death, excluding them from experiencing possible advantage from chemotherapy.Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free.
55 lakhs+ doctors trust M3 globally
Unlimited access to original articles by experts
Secure: we never sell your data
Signing up takes less than 2 mins